Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids.
Ouchi, R; Togo, S; Kimura, M; Shinozawa, T; Koido, M; Koike, H; Thompson, W; Karns, RA; Mayhew, CN; McGrath, PS; et al.
Cell Metabolism.
2019;
30:374-384.e6.
Organoids by design.
Takebe, T; Wells, JM.
Science.
2019;
364:956-959.
Approach for Communication Design for Motivation to Health Behavior.
Iizuka, S; Takebe, T; Nishii, S; Kodaka, A.
(2019)
11569 LNCS:425-436.
Defining Lineage-Specific Membrane Fluidity Signatures that Regulate Adhesion Kinetics.
Matsuzaki, T; Matsumoto, S; Kasai, T; Yoshizawa, E; Okamoto, S; Yoshikawa, HY; Taniguchi, H; Takebe, T.
Stem Cell Reports.
2018;
11:852-860.
Tumoroid a la carte: Path for personalization.
Lewis, K; Takebe, T.
Hepatology.
2018;
68:1189-1191.
Recapitulation of hepatitis B virus-host interactions in liver organoids from human induced pluripotent stem cells.
Nie, Y; Zheng, Y; Miyakawa, K; Murata, S; Zhang, R; Sekine, K; Ueno, Y; Takebe, T; Wakita, T; Ryo, A; et al.
EBioMedicine.
2018;
35:114-123.
Optimal Hypoxia Regulates Human iPSC-Derived Liver Bud Differentiation through Intercellular TGFB Signaling.
Ayabe, H; Anada, T; Kamoya, T; Sato, T; Kimura, M; Yoshizawa, E; Kikuchi, S; Ueno, Y; Sekine, K; Camp, JG; et al.
Stem Cell Reports.
2018;
11:306-316.
Digitalized Human Organoid for Wireless Phenotyping.
Kimura, M; Azuma, M; Zhang, RR; Thompson, W; Mayhew, CN; Takebe, T.
iScience.
2018;
4:294-301.
Illustrating the potency of current Good Manufacturing Practice-compliant induced pluripotent stem cell lines as a source of multiple cell lineages using standardized protocols.
Rao, MS; Pei, Y; Garcia, TY; Chew, S; Kasai, T; Hisai, T; Taniguchi, H; Takebe, T; Lamba, DA; Zeng, X.
Cytotherapy (Informa).
2018;
20:861-872.
Organoid Center Strategies for Accelerating Clinical Translation.
Takebe, T; Wells, JM; Helmrath, MA; Zorn, AM.
Cell Stem Cell.
2018;
22:806-809.